April 8th 2025
VXM01 plus avelumab was tolerable and could potentially produce clinically meaningful responses in patients with recurrent glioblastoma.
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
View More
Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma
View More
Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies
View More
Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
View More
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
View More
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
View More
Helping Caregivers and Families Feel More Able to Manage
August 11th 2016Caregivers of young adult survivors (YAS) of childhood brain tumors, usually their mothers, live dramatically altered lives as they incorporate illness management into family life and function in caregiving roles well into the survivors’ adulthood.
More Evidence That Health Insurance Status Affects Survival of Patients With Cancer
August 10th 2016Patients with cancer who have Medicaid coverage or who are uninsured are more likely to be diagnosed later and receive improper treatment for cancer, according to two recent studies, and these factors can have an impact on their survival.
Optune Approval Expanded for Newly Diagnosed GBM Patients
October 6th 2015Optune (formally the NovoTTF-100A System) in combination with adjuvant temozolomide, has been approved by the FDA to treat patients newly diagnosed with glioblastoma multiforme (GBM) following surgery, chemotherapy, and radiation therapy.